Krill Oil 4016
Natural health product licensed in Canada
- Licence holder
- Azantis LLC
- NPN or DIN-HM
- 80031394
- Status
- Active licence
- Licence date
- 12 April 2012
- Revision date
- 9 January 2013
- Form
- Gélule
- Route of administration
- Orale
- Application type
- Non traditionnelle
If this product were sold in France
No point flagged by the rules we apply.
A daily quantity is calculated only for an explicit adult oral dosage, stated per day and in a solid unit matching the product form. Ambiguous units, liquids, powders and paediatric doses are not extrapolated. A quantity not calculated is not compared with dose limits. This analysis does not constitute authorisation for sale in France or an assessment of safety or efficacy.
Composition
| Medicinal ingredient and source | Per dosage unit, according to the source | Maximum per day, adult |
|---|---|---|
| Euphausia superba Source : Organisme entier Potency : 27.5 mg DHA | Not specified | Not calculated |
| Euphausia superba Source : Organisme entier Potency : 0.1 mg Astaxanthin | Not specified | Not calculated |
Non-medicinal ingredients
Gélatine, essence de citron, Glycérine, Eau
Recommended doses in Canada
| Population | Age | Quantity per serving | Frequency |
|---|---|---|---|
| Adultes de sexe féminin | Not specified | 2 Gélule | 2 Tous les jours |
| Adultes | Not specified | 1 Gélule | 1 Tous les jours |
| Adultes | Not specified | minimum: 1 Gélule ; maximum: 3 Gélule | 2 Tous les jours |
| Adultes | Not specified | 2 Gélule | 1 Tous les jours |
Uses authorised in Canada
Text supplied in English because no French text is available.
Source of omega-3 polyunsaturated fatty acids for the maintenance of good health. Source of eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA) for the maintenance of good health. Helps in the management of the physical and emotional symptoms of premenstrual syndrome (PMS). Helps in the management of arthritis pain. Helps reduce reactive C Protein levels, a clinical marker of inflammation. In conjunction with conventional statin therapy, promotes cardiovascular health by reducing cholesterol and triglyceride/triacylglycerol levels in hyperlipidemic adults.
A use authorised in Canada is not an authorised health claim in the European Union. See the health claims register.
Warnings in Canada
No French warning text available in the imported data.
Warnings are available in English on the official record.
Source
Official Health Canada record, licence 80031394
Licensed Natural Health Products Database (LNHPD), Health Canada: licensed products, ingredients, doses, uses and risks, retrieved 27 October 2026.
Contains information licensed under the Open Government Licence – Canada (Health Canada, LNHPD)
Licence du gouvernement ouvert – Canada 2.0 (OGL-Canada 2.0)
The formula sold in Europe under the same name may differ. This information does not replace advice from a doctor or pharmacist.
List in the official revision dated (register: Licensed Natural Health Products Database (LNHPD), Health Canada: licensed products, ingredients, doses, uses and risks).
List recorded in 2013. Photograph the packaging to check whether it has changed. Photograph the packaging